Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3

Status

Completed 3Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 2NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Glioma 1Glioblastoma 1Castration Resistant Prostate Cancer 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 649Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × OTHER × TH 302 × Clear all
NCT06836726 2026-01-28

EVO

University Health Network, Toronto

Phase 2 Not yet recruiting
35 enrolled
Genitourinary

Castration Resistant Prostate Cancer

NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT02342379 2020-04-10

TH-302 in Combination With Bevacizumab for Glioblastoma

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
35 enrolled 6 charts
CNS

Glioblastoma

NCT01403610 2019-07-24

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
28 enrolled 9 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡